Colorectal Cancer and Nonsteroidal Anti-inflammatory Drugs

Advances in Pharmacology

Volumn 39, Issue C, 1997, Pages 1-20

  Smalley, Walter E ^a   DuBois, Raymond N ^b  

^a Departments of Medicine and Cell Biology

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC;

ANIMAL; CLINICAL TRIAL; COLORECTAL TUMOR; HUMAN; INCIDENCE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; UNITED STATES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; HUMANS; INCIDENCE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SULINDAC; UNITED STATES;

EID: 0030628655     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60067-8     Document Type: Article

References (69)

1. Bedi A., Pasricha P.J., Akhtar A.J., Barber J.P., Bedi G.C., Giardiello F.M., Zehnbauer B.A., Hamilton S.R., and Jones R.J. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55 (1995) 1811-1816
2. Boland C.R. The biology of colorectal cancer. Implications for pretreatment and follow-up management. Cancer (Philadelphia) 71 (1993) 4180-4186
3. Capdevila J.H., Morrow J.D., Belosludtsev Y.Y., Beauchamp D.R., DeBois R.N., and Falck J.R. The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by glutathione and glutathi-one peroxidase(s). Biochemistry 34 (1995) 3325-3337
4. DuBois R.N. Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas. Gastroenterology 108 (1995) 1310-1314
5. DuBois R.N., Tsujii M., Bishop P., Awad J.A., Makita K., and Lanahan A. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am. J. Phys. 266 (1994) G822-G827
6. DuBois R.N., Shao J., Sheng H., Tsujii M., and Beauchamp R.D. G, delay in intestinal epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 56 (1996) 733-737
7. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
8. Fearon E.R. Molecular genetic studies of the adenoma-carcinoma sequence. Adv. Intern. Med. 39 (1994) 123-147
9. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell (Cambridge, Mass.) 61 (1990) 759-767
10. Friend W.G. Sulindac suppression of colorectal polyps in Gardner's syndrome. Am. Fam. Physician. 41 (1990) 891-894
11. Gann P.H., Manson J.E., Glynn R.J., Buring J.E., and Hennekens C.H. Low-dose aspirin and incidence of colorectal tumors in a randomized trial [see comments]. J. Natl. Cancer Inst. 85 (1993) 1220-1224
12. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., and Offerhaus G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328 (1993) 1313-1316
13. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., and Willett W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121 (1994) 241-246
14. Giovannucci E., Egan K.M., Hunter D.J., Stampfer M.J., Colditz G.A., Willett W.C., and Speizer F.E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333 (1995) 609-614
15. Greenberg E.R., Baron J.A., Freeman D.H.J., Mandel J.S., and Haile R. Reduced risk of large-bowel adenomas among aspirin users. J. Natl. Cancer Inst. 85 (1993) 912-916
16. Hamilton S.R. The molecular genetics of colorectal neoplasia. Gastroenterology 105 (1993) 3-7
17. Hixson L.J., Earnest D.L., Fennerty M.B., and Sampliner R.E. NSAID effect on sporadic colon polyps. Am. J. Gastroenterol. 88 (1993) 1652-1656
18. Hixson L.J., Alberts D.S., Krutzsch M., Einsphar J., Brendel K., Gross P.H., Paranka N.S., Baier M., Emerson S., and Pamukcu R. Antiproliferative effect of nonste-roidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol. Bio-markers Prev. 3 (1994) 433-438
19. Hla T., and Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7384-7388
20. Holtzman M.J., Turk J., and Shornick L.P. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J. Biol. Chem. 267 (1992) 21438-21445
21. Jones D.A., Carlton D.P., Mclntyre T.M., Zimmerman G.A., and Prescott S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem. 268 (1993) 9049-9054
22. Kargman S., O'Neill G., Vickers P., Evans J., Mancini J., and Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55 (1995) 2556-2559
23. Kinzler K.W., Nilbert M.C., Su L.K., Vogelstein B., Bryan T.M., Levy D.B., Smith K.J., Preisinger A.C., Hedge P., McKechnie D., et al. Identification of FAP locus genes from chromosome 5q21. Science 253 (1991) 661-665
24. Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., and Herschman H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266 (1991) 12866-12872
25. Kune K.A., Kune S., and Watson L.F. Colorectal cancer risk, chronic illnesses, operations and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 48 (1988) 4399-4404
26. Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., and Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101 (1991) 635-639
27. Landenheim J., Garcia G., Titzer D., Herzenberg H., Lavori P., Edson R., and Omary M.B. Effect of sulindac on sporadic colonic polyps. Gastroenterology 108 (1995) 1083-1087
28. Liu T., Mokuolu A.O., Rao C.V., Reddy B.S., and Holt P.R. Regional chemo-prevention of carcinogen-induced tumors in rat colon. Gastroenterology 109 (1995) 1167-1172
29. Logan R.F., Little J., Hawtin P.G., and Hardcastle J.D. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme. B.M.J. 307 (1993) 285-289
30. Lu X., Xie W., Reed D., Bradshaw W.S., and Simmons D.L. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenase in chicken embryo fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7961-7965
31. MacPhee M., Chepenik K., Liddell R., Nelson K., Siracusa L., and Buchberg A. The secretory phospholipase A2 gene is a candidate for the Motnl locus, a major modifier of Apcmin-induced intestinal neoplasia. Cell (Cambridge, Mass.) 81 (1995) 957-966
32. Marnett L. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52 (1992) 5575-5589
33. Meade E.A., Smith W.L., and DeWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268 (1993) 6610-6614
34. Miller A.B., Howe G.R., and Jain M. Food items and food groups as risk factors in a case-control study of diet and colon cancer. Int. J. Cancer 32 (1983) 155-162
35. Muscat J.E., and Wynder E.L. Anti-inflammatory drugs and rheumatoid arthritis. J. Natl. Cancer Inst. 85 (1993) 921-922
36. Muscat J.E., Stellman S.D., and Wynder E.L. Nonsteroidal antiinflammatory drugs and coloreetal cancer. Cancer (Philadelphia) 74 (1994) 1847-1854
37. Nishisho I., Nakamura Y., Miyoshi Y., Miki Y., Ando H., Horii A., Koyama K., Utsuno-miya J., Baba S., and Hedge P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253 (1991) 665-669
38. Nugent K.P., Farmer K.C., Spigelman A.D., Williams C.B., and Phillips R.K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80 (1993) 1618-1619
39. Paganini-Hill A., Chao A., Ross R.K., and Henderson B.E. Aspirin use and chronic diseases: A cohort study of the elderly. B.M.J. 299 (1989) 1247-1250
40. Peipins L.A., and Sandier R.S. Epidemiology of colorectal adenomas. Epidemiol. Rev. 16 (1994) 273-297
41. Peleg I.I., Maibach H.T., Brown S.H., and Wilcox C.M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med. 154 (1994) 394-399
42. Peleg I.I., Maibach H.T., Brown S.H., and Wilcox C.M. Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 321 (1989) 129-135 Physicians' Health Study Group.
43. Peleg I.I., Maibach H.T., Brown S.H., and Wilcox C.M. Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 318 (1995) 262-264 Physicians' Health Study Group
44. Piazza G.A., Rahm A.L., Krutzsch M., Sperl G., Paranka N.S., Gross P.H., Brendel K., Burt R.W., Alberts D.S., Pamukcu R., and Ahnen D.J. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55 (1995) 3110-3116
45. Powell S.M., Zilz N., Beazer-Barclay Y., Bryan T.M., Hamilton S.R., Thibodeau S.N., Vogelstein B., and Kinzler K.W. APC mutations occur early during colorectal tumorigenesis. Nature (London) 359 (1992) 235-237
46. Rao C.V., Rivenson A., Simi B., Zang F., Kelloff G., Steele V., and Reddy B.S. Chemoprevention of colon carcinogenesis by sulindaC., a nonsteroidal anti-inflammatory agent. Cancer Res. 55 (1995) 1464-1472
47. Reddy B.S., Maruyama H., and Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 47 (1987) 5340-5346
48. Reddy B.S., Nayini J., Tokumo K., Rigotty J., Zang E., and Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D, L-alpha-difluoromethylornithine, an ornithine decarboxyl-ase inhibitor, in diet. Cancer Res. 50 (1990) 2562-2568
49. Reddy B.S., Tokumo K., Kulkarni N., Aligia C., and Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis (London) 13 (1992) 1019-1023
50. Reddy B.S., Rao C.V., Rivenson A., and Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (London) 14 (1993) 1493-1497
51. Rigau J., Pique J.M., Rubio E., Planas R., Tarrech J.M., and Bordas J.M. Effects of long-term sulindac therapy on colonic polyposis. Ann. Intern. Med. 115 (1991) 952-954
52. Rosenberg L., Palmer J.R., Zauber A.G., Washauer M.E., Stolley P.D., and Shapiro S. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst. 83 (1991) 355-358
53. Rustgi A.K. Molecular genetics and colorectal cancer. Gastroenterology 104 (1993) 1223-1225
54. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., and Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55 (1995) 3785-3789
55. Schreinemachers D.M., and Everson R.B. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5 (1994) 138-146
56. Shimokawa T., and Smith W.L. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J. Biol. Chem. 267 (1992) 12387-12392
57. Smith W.L., and Marnett L.J. Prostaglandin endoperoxide synthase: Structure and catalysis. Biochim. Biophys. Acta 1083 (1991) 1-17
58. Su L.K., Vogelstein B., and Kinzler K.W. Association of the APC tumor suppressor protein with catenins. Science 262 (1993) 1734-1737
59. Suh O., Mettlin C., and Petrelli N.J. Aspirin use, cancer and polyps of the large bowel. Cancer (Philadelphia) 72 (1993) 1171-1177
60. Thun M.J., Namboodiri M.M., and Heath C.W.J. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325 (1991) 1593-1596
61. Tonelli F., and Valanzano R. Sulindac in familial adenomatous polyposis. Lancet 342 (1993) 1120
62. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell (Cambridge, Mass.) 83 (1995) 493-501
63. Vane J. Towards a better aspirin. Nature (London) 367 (1994) 215-216
64. Waddell W.R., and Loughry R.W. Sulindac for polyposis of the colon. J. Surg. Oncol. 24 (1983) 83-87
65. Waddell W.R., Gasner G.F., Cerise E.J., and Loughry R.W. Sulindac for polyposis of the colon. Am. J. Surg. 157 (1989) 175-178
66. Williams C.W., Luongo C., Radhika A., Zhang T., Lamps L.W., Nanney L.B., Beauchamp R.D., and DuBois R.N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111 (1996) 1134-1140
67. Winde G., Gumbinger H.G., Osswald H., Kemper F., and Bunte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: Clinical results of a dose-finding study on rectal sulindac administration. Int. J. Colorectal Dis. 8 (1993) 13-17
68. Wynder E.L., Kajitani T., Ishikawa S., Dodo H., and Takano A. Environmental factors of cancer of colon and rectum. II. Japanese epidemiological data. Cancer (Philadelphia) 23 (1969) 1210-1220
69. Yokoyama C., and Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun. 165 (1989) 888-894